Moreover, the findings of the current study are consistent with those of Kim, which revealed that PAR-1 antagonist treatment reduced thrombin expression in an experimental autoimmune encephalomyelitis model (Kim et al., 2015). The gene discussed is F2R; the disease is experimental autoimmune encephalomyelitis.